Yazar "Ozturk, A. Alper" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Preparation, radiolabeling and cell culture studies of chitosan coated PLGA nanoparticles as a potential cancer diagnostic agent
    (Marmara Univ, 2022) Ekinci, Meliha; Ozturk, A. Alper; Ilem-Ozdemir, Derya
    Using the nanoprecipitation process, chitosan coated poly lactic-co-glycolic acid (PLGA) based polymeric nanoparticle formulations of two molecular weights were developed as a possible cancer cell diagnostic agent. Photon correlation spectroscopy was used to measure the particle size, distribution [polydispersity index (PDI)], and zeta potential values of developed nanoparticle formulations. The F1 [low molecular weight PLGA (Resomer (R) RG 503 H)] and F2 [high molecular weight PLGA (Resomer (R) RG 504 H)] formulations were then directly labeled with Technetium-99m ([99mTc]Tc) using stannous salts (chloride) as a reducing agent. The radiochemical purity (RP) and in vitro stability in different mediums of the formulations were assessed using ascending radioactive thin layer chromatography (RTLC) method. The cell incorporation of [99mTc]Tc labeled F1 and F2 formulations, as well as Reduced/Hydrolized [99mTc]NaTcO4 (R/H-[99mTc]NaTcO4) in the MCF-7 (breast cancer cell line) cells, was then assessed. The nanoparticles had a middle size of 408.9 +/- 3.626 nm to 421.3 +/- 7.205 nm, a PDI value of 0.310 +/- 0.055 to 0.330 +/- 0.066, and a positive charge of +70.5 +/- 1.4 mV to +75.5 +/- 3.8 mV, according to the characterization results. F1 and F2 formulations were effectively radiolabeled with [99mTc]Tc, and their RP was found to be over 98% in both cases. When compared to [99mTc]Tc-F1 (45.091 +/- 2.254%) and R/H-[99mTc]NaTcO4 (8.527 +/- 0.426%), the incorporation percentages of [99mTc]Tc-F2 (70.756 +/- 3.537%) were shown to be higher in cancer cell lines (breast cancer cells, MCF-7). According to this research, radiolabeled chitosan coated PLGA nanoparticles ([99mTc]Tc-F2) could be suggested as promising cancer detection formulations. However, further investigations, such as biodistribution studies, should be performed.
  • Küçük Resim Yok
    Öğe
    The use of Lamivudine-loaded PLGA nanoparticles in the diagnosis of lung cancer: Preparation, characterization, radiolabeling with Tc-99m and cell binding
    (Elsevier, 2022) Ekinci, Meliha; Ozturk, A. Alper; Santos-Oliveira, Ralph; Ilem-Ozdemir, Derya
    Lung cancer is the leading cause of death (male and female) globally, responsible for over 1.8 million deaths. Although there have been some advances in the treatment of lung cancer, the early detection remains an issue globally. The necessity of new drugs able to efficiently accumulate and image lung cancer is quite required. In this study was developed PLGA nanoparticles loaded with Lamivudine (PLGA-NPs-LAM). The PLGA-NPs-LAM was characterized, radiolabeled with radioactive technetium (Tc-99m), and in vitro evaluated. The results showed a medium size of 203.667 +/- 1.436 nm, with a PDI value of 0.063 +/- 0.052, and a superficial charge of-4.597 +/- 0.368 mV. The entrapment efficacy demonstrated was 48.346 +/- 1.742% of LAM. Radiolabeling of PLGA-NPs-LAM with Technetium-99 m (Tc-99m) showed high efficiency (> 93%). The in vitro assay human lung cancer (A-549) and human fibroblast (L-929) cell lines showed that the NPs were higher uptake in A-549 line than L-929. The data demonstrated that [Tc-99m]Tc-PLGA-NPs-LAM may be a promising agent for lung cancer diagnosis.